Identification of Human Endogenous Retrovirus-Specific T Cell Responses in Vertically HIV-1-Infected Subjects

Ravi Tandon,1* Devi SenGupta,1 Lishomwa C. Ndhlovu,1# Raphaella G. S. Vieira,1 R. Brad Jones,3 Vanessa A. York,1 Vinicius A. Vieira,1 Elizabeth R. Sharp,1 Andrew A. Wiznia,2 Mario A. Ostrowski,3 Michael G. Rosenberg,2 and Douglas F. Nixon1**

Division of Experimental Medicine, Department of Medicine, University of California, San Francisco, California 941101; Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York 104612; and Department of Immunology, University of Toronto, Toronto, ON M5S 1A8, Canada3

Received 15 June 2011/Accepted 18 August 2011

Human endogenous retrovirus (HERV)-specific T cell responses in HIV-1-infected adults have been reported. Whether HERV-specific immunity exists in vertically HIV-1-infected children is unknown. We performed a cross-sectional analysis of HERV-specific T cell responses in 42 vertically HIV-1-infected children. HERV (H, K, and L family)-specific T cell responses were identified in 26 of 42 subjects, with the greatest magnitude observed for the responses to HERV-L. These HERV-specific T cell responses were inversely correlated with the HIV-1 plasma viral load and positively correlated with CD4+ T cell counts. These data indicate that HERV-specific T cells may participate in controlling HIV-1 replication and that certain highly conserved HERV-derived proteins may serve as promising therapeutic vaccine targets in HIV-1-infected children.

Studies of HIV-1 pathogenesis in vertically HIV-1-infected infants before the advent of antiretroviral therapy (ART) showed persistently high levels of plasma viremia for the first year of life, followed by a decline in viral burden by the age of three (18, 19). Moreover, a higher proportion of HIV-1-infected infants exhibited rapid disease progression to AIDS and death than that seen for adults (22). While remarkable progress has been made toward wider access to antiretroviral drugs, the majority of HIV-1-infected children worldwide remain untreated, resulting in high mortality rates among HIV-1-infected children less than 5 years of age.

Vertical transmission rates in the United States declined by over two-thirds with the introduction in 1994 of perinatal zidovudine (ZDV) prophylaxis, as per the ACTG 076 protocol (5, 27). Further reductions in transmission, to less than 2%, have been achieved with more effective antenatal and perinatal chemoprophylactic regimens and improved obstetric practices (14, 27). However, despite the availability of potent drugs, HIV-1-infected infants and children continue to have difficulty controlling plasma viremia due to multiple factors unique to pediatrics, including drug formulation and palatability issues, altered pharmacokinetics, novel toxicities, and caregiver-related problems. These obstacles have led to high levels of drug resistance among these patients, limiting future treatment options and increasing the financial and social costs of treating this disease.

The human genome is littered with retroviral gene elements known as human endogenous retroviruses (HERV). HERV comprise around 8 to 10% of the entire human genome and are thought to represent footprints of ancient retroviral infections which incorporated into germ line DNA (26). There are conserved HERV-derived proteins may serve as promising therapeutic vaccine targets in HIV-1-infected children.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Median value (IQR) or no. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Demographics</td>
<td></td>
</tr>
<tr>
<td>Median age (yr)</td>
<td>14.7 (12.4–17.8)</td>
</tr>
<tr>
<td>Male/female</td>
<td>21 (50%)/21 (50%)</td>
</tr>
<tr>
<td>Race</td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>26 (62%)</td>
</tr>
<tr>
<td>Hispanic</td>
<td>16 (38%)</td>
</tr>
<tr>
<td>Disease characteristics</td>
<td></td>
</tr>
<tr>
<td>1994 CDC class</td>
<td></td>
</tr>
<tr>
<td>N (none)</td>
<td>4 (9.5%)</td>
</tr>
<tr>
<td>A (mild)</td>
<td>16 (38%)</td>
</tr>
<tr>
<td>B (moderate)</td>
<td>16 (38%)</td>
</tr>
<tr>
<td>C (AIDS defining)</td>
<td>6 (14.5%)</td>
</tr>
<tr>
<td>CD4 cells (%)</td>
<td>28 (17.8–31.5)</td>
</tr>
<tr>
<td>CD4 cell count (cells/μl)</td>
<td>502 (354–1,762)</td>
</tr>
<tr>
<td>HIV-1 RNA (copies/ml)</td>
<td>4,898 (567–34,250)</td>
</tr>
<tr>
<td>Antiretroviral therapy</td>
<td></td>
</tr>
<tr>
<td>NRTIs</td>
<td>12 (28.6%)</td>
</tr>
<tr>
<td>NRTIs + NNRTIs</td>
<td>5 (12%)</td>
</tr>
<tr>
<td>NRTIs + PI</td>
<td>18 (43%)</td>
</tr>
<tr>
<td>Complex ART (≥3 classes)</td>
<td>7 (16.4%)</td>
</tr>
</tbody>
</table>

* Corresponding author. Mailing address for Douglas F. Nixon: Division of Experimental Medicine, University of California San Francisco, Department of Medicine, Building 3, Room 603, 1001 Potrero Avenue, San Francisco, CA 94110. Phone: (415) 206-5518. Fax: (415) 206-5581. E-mail: douglas.nixon@ucsf.edu.
** Present address: Hawai‘i Center for AIDS, University of Hawai‘i, John A. Burns School of Medicine, Honolulu, HI 96813. Phone: (808) 692-1659. Fax: (808) 692-1984. E-mail: rtandon@hawaii.edu.
### 1
# Present address: Hawai‘i Center for AIDS, University of Hawai‘i, John A. Burns School of Medicine, Honolulu, HI 96813.
## 1
† The authors have paid a fee to allow immediate free access to this article.
three separate classes of HERV, each of which is further subdivided into different families. Most HERV are defective due to the accumulation of mutations and deletions. However, some HERV families, e.g., HERV-H, HERV-W, HERV-K, and HERV-L, possess intact open reading frames encoding structural gene products (1, 3, 8, 15, 16) and are able to express these and other viral products under certain conditions (4, 13). In addition, some HERV have been shown to be associated with some autoimmune diseases and cancers (20, 21). In certain circumstances, exogenous retrovirus infections such as HIV-1 have been shown to induce HERV-K expression (6, 7, 11). We have previously shown that HIV-1-infected adults can mount anti-HERV-specific T cell responses and that an inverse relationship exists between the magnitude of the HERV-specific T cell response and the level of HIV-1 viremia in untreated patients, in both the early (10) and the chronic (23) phases of the disease. This finding suggests that HERV-specific immunity may be contributing to the control of viral replication in adults. The purpose of this study was to determine whether vertically HIV-1-infected children can also mount an anti-HERV response.

We performed a cross-sectional study to investigate HERV-specific T cell responses in 42 vertically HIV-1-infected patients. Study subjects were recruited from a large outpatient pediatric HIV-1 clinic located at Jacobi Medical Center, Bronx, NY (Table 1). We obtained heparinized blood samples with appropriate informed consent under approval from the University of California, San Francisco (UCSF) and Jacobi Medical Center institutional review board (IRB) committees. All patients were self-identified as African American or Hispanic. The plasma HIV-1 RNA load was measured with an Amplicor HIV-1 monitor (Roche Diagnostic Systems), which has a lower limit of quantification of 50 copies of viral RNA/ml. HERV and HIV-1 peptides were manufactured as de-
Cryopreserved peripheral blood mononuclear cells (PBMC) from study participants were thawed and screened for responses against a set of 28 HERV peptides using a gamma interferon (IFN-\(\gamma\)) enzyme-linked immunosorbent spot (ELISPOT) assay. All samples were tested in duplicate (at 10^5 cells per well) with the peptides at a concentration of 100 \(\mu\)g/ml per well. The high peptide concentration was used in the ELISPOT assays to detect low-avidity responses. This concentration elicited responses in the range of 50 to 715 spots per 10^6 PBMC. The numbers of spots for duplicate wells were averaged and normalized to numbers of IFN-\(\gamma\)-secreting spot-forming units (SFU) per 1 \(\times\) 10^6 PBMC. The spot values from medium control wells were subtracted, after which a response was considered positive if it was >50 spots per million PBMC and >2 times higher than that in the background medium. HLA restriction was performed using patient-derived PBMC plus peptide-pulsed or unpulsed single-HLA allele B cell transfectants as targets in the ELISPOT assay. HLA typing was performed using an All Set HLA typing kit (Invitrogen, Eugene, OR).

Twenty-six patients had at least one HERV-specific T cell response. The breadth and magnitude of the responses varied (Fig. 1a). While some HERV peptides failed to elicit any response, most of the peptides stimulated a response in one or more subjects (Fig. 1b). No anti-HERV T cell responses were observed for 10 healthy HIV-1-uninfected controls (median age, 46 years; interquartile range [IQR], 32 to 51 years) (Fig. 1c). Multiple full-length open reading frames for all HERV-K proteins have been found in the human genome. Therefore, we hypothesized that many of the HERV-specific T cell responses would match epitopes from the HERV-K family. To our surprise, HERV-L- and HERV-H-specific epitopes elicited high-magnitude T cell responses in many subjects (Fig. 1a and b).

We also examined whether anti-HERV T cell responses were inversely related to the HIV-1 plasma viral load. There was a significant negative correlation between total HERV-specific T cell responses and HIV-1 plasma viral load (\(P = 0.006\), Spearman \(r = -0.417\)) (Fig. 2a). In addition, a significant negative correlation was also found when the average combined HERV-specific T cell responses were compared with the HIV-1 plasma viral load (\(P = 0.006\), Spearman \(r = \ldots\))
—0.416) (Fig. 2b). No significant correlation was found when anti-HERV and anti-HIV-1 T cell responses were compared (data not shown), suggesting that these two responses are independent and that within a given peptide set, children with HERV-specific T cell responses do not necessarily mount concomitant HIV-1-specific responses. We also detected a significant direct correlation between the total HERV-specific T cell response and CD4 T cell count (P = 0.0496, Spearman r = 0.304) (Fig. 2c). CD4 T cells may influence the quality of the CD8 T cell response, and we would predict that patients with higher CD4 T cell levels and greater degrees of immunocompetence would generate robust anti-HERV responses with enhanced functional capacities. This is consistent with our observation of a direct association between the HERV response and the CD4 T cell count.

While most perinatal HIV-1 transmission takes place at the time of birth, it is well established that maternal-fetal transmission of HIV-1 can also occur throughout gestation (9, 12, 25). Infection in utero could lead to the induction of immunological tolerance to HIV-1 (17) as well as to any induced HERV products. Our data clearly demonstrate that vertically infected children can mount anti-HERV responses. However, the impact of antiretroviral therapy on HIV-1 replication and HERV expression, and its corresponding influence on the host HERV and HIV-1 response, needs to be further addressed before any protective function can be attributed to HERV-specific responses.

Previous studies have shown that ART can diminish but not fully extinguish HERV RNA expression and, by inference, HERV protein production. This question was approached in a more systematic fashion by performing a longitudinal study of CD8 T cell responses to an HLA-restricted HERV peptide within a single treatment-experienced patient (S1) initiating potent combination antiretroviral therapy (cART). In order to determine the HLA restriction of the HERV-K reverse transcriptase (RT) FAFTIPAI (F8) peptide-specific T cell response, we used single-allele B cell transfectants to determine the restriction of the F8 peptide. Briefly, 10^6 B cell transfectants were pulsed with peptide for 1 h at 37°C followed by three washes before cells were added to a standard ELISPOT assay with PBMC (23). F8-pulsed HLA-A*02-positive B cell transfectants elicited a strong IFN-γ response when incubated with PBMC derived from S1, whereas F8-pulsed HLA-unmatched (HLA-A*02-negative) B cell transfectants elicited only a background response, indicating that the F8 response was restricted by HLA-A*02 (Fig. 3a). Of note, the HERV F8 response can also be restricted by HLA-B51 in other individuals (23).

The F8-specific T cell response was dose dependent, as the strength of the response (in SFU/million PBMC) diminished with decreasing concentrations of the F8 peptide (Fig. 3b). The response to the F8 peptide was highest in the setting of detectable but low HIV-1 viremia (3,900 copies/ml) and stable CD4 T cell count (674 cells/mm^3) in August 2005 and, interestingly, declined as the HIV-1 viral load peaked at 165,223 copies/ml in April 2010, before the patient began a more effective suppressive cART regimen. The F8 response remained low in September 2010 in the setting of poor immune reconstitution (CD4 T cell count, 267 cells/mm^3) and an HIV-1 viral load that had begun to rebound to 331 copies/ml after a brief period of transiently suppressive cART (Fig. 4). This trend is in agreement with our recent published data on untreated adults with chronic HIV-1 infection, showing that untreated HIV-1-infected individuals with the ability to control viral replication in the absence of treatment (“controllers”) had stronger and broader HERV-specific T cell responses than patients with ART suppression of viral replication (ART-suppressed patients), virologic noncontrollers, immunologic progressors, and uninfected controls (23). In addition, we showed that
anti-HERV T cell responses were associated with lower HIV-1 viral loads and higher CD4+ counts in untreated HIV-1-infected adults (23). Our data suggest that anti-HERV T cell responses have the potential to act against HIV-1, but we cannot rule out the possibility that stronger HERV responses may simply be a reflection of a more intact immunological status. Recent data from our lab showed that HIV-1-infected subjects with preserved CD4+ T cell counts had no differences in their cytomegalovirus (CMV) pp65 T cell responses, while progressors with low CD4+ T cell counts had lower CMV pp65 responses than controllers and highly active antiretroviral therapy (HAART)-suppressed patients (23).

Due to current treatment guidelines, most vertically HIV-1-infected individuals in the United States are prescribed ART, albeit with variable levels of adherence. Imperfect adherence leads to fluctuating levels of viremia and eventually leads to drug resistance and treatment failure. We identified one such subject (S1) with a history of poor adherence to ART and high-grade viremia who was found to mount an HLA-restricted response to a particular HERV-K RT peptide, FI8. The kinetics of this patient’s HERV response were consistent with our cross-sectional data demonstrating that individuals who lack strong HERV responses have high HIV-1 viral loads and low CD4+ T cell counts. Since older vertically infected cohorts like the one studied here do not show that HIV-1-infected subjects with preserved CD4+ counts in untreated HIV-1-infected adults (23).

While HIV-1 undergoes an intrinsically high degree of mutation and diversification during the course of infection, HERV proteins expressed on the surface of HIV-1-infected cells remain conserved. Since anti-HERV-specific cytotoxic T cells have the potential to target any HIV-1-infected cell expressing these endogenous retroviral antigens irrespective of HIV-1 sequence variation, they may serve as excellent therapeutic or preventive vaccine candidates.

This work was funded by a Pfizer-sponsored research agreement, NIH/NIAID grants RO1 AI076145, K24AI069994, AI76959, and AI84113, the CFAR Network of Integrated Clinical Systems (CNICS; grant 1 R24 AI076039-1), UCSF Gladstone Institute of Virology & Immunology Center for AIDS Research (CFAR), an NIH-funded program (P30 AI027763), and the Fogarty International Center (grant D43 TW00003). This work was also supported in part by the UCSF Clinical and Translational Science Institute (UL1 RR024131), the American Foundation for AIDS Research (100710-40-RGRL), and the Ragon Institute, Boston, MA.

We thank Lewis Lanier (UCSF) for providing single-HLA allele transfectant B cells used for HLA restriction experiments and Neil Sheppard, Peter Loudon, and James Merson (Pfizer, Inc.) for helpful discussions.

R.B.J., M.A.O., and D.F.N. are listed as inventors on a patent application related to this work.

REFERENCES